LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC announces the filing of a class action lawsuit against Egalet Corporation (“Egalet” or the “Company”) (Nasdaq: EGLT). Investors who purchased or otherwise acquired Egalet shares between December 15, 2015, and January 9, 2017, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the March 28, 2017 lead plaintiff deadline.
If you purchased or otherwise acquired Egalet shares and would like more information regarding the class action lawsuit, we encourage you to click here, or contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at firstname.lastname@example.org.
On January 9, 2017, Egalet released a statement regarding approval for its product Arymo ER. The same day, the U.S. Federal Drug Administration stated that a competitor product MorphaBond “has marketing exclusivity for labeling describing the expected reduction of abuse of single-entity extended-release morphine by the intranasal route due to physicochemical properties.”
Due to MorphaBond’s exclusivity within this market, “no other single-entity extended-release morphine product submitted in an abbreviated new drug application or 505(b)(2) application can be approved for that use at this time.”
When this information was revealed to the investing public, the value of Egalet declined, causing investors severe harm.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at email@example.com.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.